Workflow
Foreign Currency Risks
icon
Search documents
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
ZACKSยท 2025-04-16 15:25
Core Insights - STERIS plc's Healthcare business is experiencing growth due to strong U.S. procedure volumes, favorable pricing, and market share gains, particularly in the Applied Sterilization Technologies (AST) segment [1][4][6] - The company has shown resilience in its stock performance, with a 10.4% increase over the past year, contrasting with a 10.4% decline in the industry [2] - Financial health indicators are positive, with a market capitalization of $22.01 billion and an earnings yield of 4.4%, significantly higher than the industry's -3.2% [2] Healthcare Segment Performance - The Healthcare segment reported a 7% year-over-year revenue growth in the third quarter of fiscal 2025, driven by a 9% increase in consumable revenues and a 13% rise in service revenues [4] - Order growth exceeded 10% in the fiscal third quarter, resulting in a healthcare backlog of $435 million [5] - Margins improved due to increased volume, favorable pricing, and productivity gains that offset labor inflation [5] AST Segment Insights - The AST segment achieved a 10% year-over-year growth in the fiscal third quarter, with service revenues also increasing by 10% [6] - The company is witnessing a rebound in bioprocessing demand and stable global demand from MedTech customers, with expectations for continued growth in bioprocessing revenues [6] Financial Health - As of the fiscal third quarter, STERIS reduced its long-term debt to $2.04 billion, a 5.6% decrease from the previous quarter [7] - The company had cash and cash equivalents of $155.2 million, exceeding its short-term debt of $125 million, resulting in a total debt-to-capital ratio of 25.2% [7] Macroeconomic Challenges - The global macroeconomic environment poses challenges, with rising healthcare costs impacting the company's financial operations [8][10] - Foreign currency exchange rate fluctuations affect nearly 30% of the company's revenues and costs, leading to a revised revenue growth rate of approximately 6% due to negative currency impacts [11]